Phibro Animal Health (NASDAQ:PAHC) Given a $26.00 Price Target by Morgan Stanley Analysts

Phibro Animal Health (NASDAQ:PAHC) has been given a $26.00 price target by equities research analysts at Morgan Stanley in a note issued to investors on Wednesday, MarketBeat Ratings reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 5.05% from the company’s previous close.

Several other analysts also recently weighed in on PAHC. Wall Street Zen upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. BNP Paribas upgraded Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price objective for the company in a research report on Monday, June 16th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $21.80.

Phibro Animal Health Stock Performance

Shares of NASDAQ PAHC opened at $24.75 on Wednesday. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The stock’s fifty day moving average price is $22.14 and its two-hundred day moving average price is $21.94. Phibro Animal Health has a one year low of $16.16 and a one year high of $26.55. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 31.73, a P/E/G ratio of 0.47 and a beta of 0.74.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.11. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. The firm had revenue of $347.80 million for the quarter, compared to analyst estimates of $352.41 million. On average, equities analysts forecast that Phibro Animal Health will post 1.95 EPS for the current year.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in Phibro Animal Health by 0.6% in the fourth quarter. Rhumbline Advisers now owns 76,582 shares of the company’s stock worth $1,608,000 after purchasing an additional 484 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Phibro Animal Health by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 98,783 shares of the company’s stock worth $2,074,000 after purchasing an additional 2,696 shares in the last quarter. Ieq Capital LLC bought a new stake in Phibro Animal Health in the fourth quarter worth approximately $302,000. Bank of New York Mellon Corp increased its holdings in Phibro Animal Health by 2.9% in the fourth quarter. Bank of New York Mellon Corp now owns 272,632 shares of the company’s stock worth $5,725,000 after purchasing an additional 7,747 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in Phibro Animal Health by 2.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 24,042 shares of the company’s stock worth $505,000 after purchasing an additional 503 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.